Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.

The Journal of clinical endocrinology and metabolism - 1 Feb 2012

Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavò S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea M L, Lania A G, Spada A

Abstract excerpt

CONTEXT: The influence of full-length GH receptor (GHR) and exon 3-deleted GHR (d3GHR) on responsiveness to pegvisomant (PEG-V) in acromegalic patients is uncertain. OBJECTIVE: The aim of the study was to assess the distribution of GHR genotypes in a large series of patients on PEG-V therapy and their influence on treatment efficacy and adverse effects. DESIGN AND SETTING: A cross-sectional multicenter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acromegaly
Share to Adenoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Human Growth Hormone

Share to Receptors, Somatotropin

Share to Somatostatin

Source

Identifiers

PMID: 22162472
DOI: 10.1210/jc.2011-1769

Genes

GHR
SST

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.PMID 22162472Read ↗

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3Semantic proximity Read ↗

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.Semantic proximity Read ↗

Genetic Predictors of Response to Different Medical Therapies in Acromegaly.Semantic proximity Read ↗

Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.Semantic proximity Read ↗

The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.Semantic proximity Read ↗

Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients.Semantic proximity Read ↗

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in AcromegalySemantic proximity Read ↗

Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly.Semantic proximity Read ↗

Treatment of acromegaly in the era of personalized and predictive medicine.Semantic proximity Read ↗

The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.Semantic proximity Read ↗

Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with AcromegalySemantic proximity Read ↗

Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.